PL3082850T3 - Celowana szczepionka DNA MSLN w immunoterapii nowotworu - Google Patents

Celowana szczepionka DNA MSLN w immunoterapii nowotworu

Info

Publication number
PL3082850T3
PL3082850T3 PL14821508T PL14821508T PL3082850T3 PL 3082850 T3 PL3082850 T3 PL 3082850T3 PL 14821508 T PL14821508 T PL 14821508T PL 14821508 T PL14821508 T PL 14821508T PL 3082850 T3 PL3082850 T3 PL 3082850T3
Authority
PL
Poland
Prior art keywords
dna vaccine
cancer immunotherapy
targeting dna
msln targeting
msln
Prior art date
Application number
PL14821508T
Other languages
English (en)
Inventor
Marco Springer
Heinz Lubenau
Original Assignee
Vaximm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Gmbh filed Critical Vaximm Gmbh
Publication of PL3082850T3 publication Critical patent/PL3082850T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42Salmonella
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL14821508T 2013-12-18 2014-12-17 Celowana szczepionka DNA MSLN w immunoterapii nowotworu PL3082850T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005896 2013-12-18
PCT/EP2014/003403 WO2015090584A1 (en) 2013-12-18 2014-12-17 Novel msln targeting dna vaccine for cancer immunotherapy
EP14821508.0A EP3082850B1 (en) 2013-12-18 2014-12-17 Msln targeting dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
PL3082850T3 true PL3082850T3 (pl) 2020-01-31

Family

ID=49876343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14821508T PL3082850T3 (pl) 2013-12-18 2014-12-17 Celowana szczepionka DNA MSLN w immunoterapii nowotworu

Country Status (19)

Country Link
US (2) US20160317634A1 (pl)
EP (1) EP3082850B1 (pl)
JP (1) JP6662787B2 (pl)
KR (1) KR20160130979A (pl)
CN (1) CN106061500A (pl)
AU (1) AU2014365900B2 (pl)
BR (1) BR112016014405A2 (pl)
CA (1) CA2932388A1 (pl)
DK (1) DK3082850T3 (pl)
ES (1) ES2747772T3 (pl)
HU (1) HUE045567T2 (pl)
IL (1) IL246170B (pl)
LT (1) LT3082850T (pl)
MX (1) MX2016007939A (pl)
PL (1) PL3082850T3 (pl)
RU (1) RU2016129044A (pl)
SG (1) SG11201604911VA (pl)
SI (1) SI3082850T1 (pl)
WO (1) WO2015090584A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
AU2014256457B2 (en) * 2013-04-25 2018-02-22 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1
PL3082850T3 (pl) 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu
EP3310379B1 (en) * 2015-06-18 2019-11-06 Vaximm AG Vegfr-2 targeting dna vaccine for combination therapy
MX2019000415A (es) 2016-07-13 2019-03-28 Vaximm Ag Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.
JP2019533698A (ja) * 2016-11-04 2019-11-21 バクシム アクチェンゲゼルシャフト 併用療法のためのwt1標的指向性dnaワクチン
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
KR20190125481A (ko) * 2017-03-17 2019-11-06 백심 아게 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
WO2019118760A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
JP7598315B2 (ja) 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用dnaワクチンを標的とするネオアンチゲン
CA3162994A1 (en) 2020-01-13 2021-07-22 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
CN119751681A (zh) * 2024-12-30 2025-04-04 北京百替生物技术有限公司 抗间皮素的单链抗体、mRNA及其应用和核酸药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US9200036B2 (en) * 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
EP1575500A4 (en) * 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
CN1859851A (zh) * 2002-07-12 2006-11-08 约翰斯霍普金斯大学 间皮素疫苗与模型系统
WO2006137836A2 (en) 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
AU2006220500A1 (en) 2005-03-09 2006-09-14 Board Of Regents, The University Of Texas System Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
JP6251179B2 (ja) * 2011-12-22 2017-12-20 バクシム アクチェンゲゼルシャフト 弱毒化サルモネラ株を高収量で生産する方法
JP2015533491A (ja) 2012-09-17 2015-11-26 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 染色体組換え操作に基づく多機能性経口ワクチン
AU2014256457B2 (en) 2013-04-25 2018-02-22 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1
PL3082850T3 (pl) 2013-12-18 2020-01-31 Vaximm Gmbh Celowana szczepionka DNA MSLN w immunoterapii nowotworu

Also Published As

Publication number Publication date
AU2014365900B2 (en) 2020-04-09
SG11201604911VA (en) 2016-07-28
SI3082850T1 (sl) 2020-01-31
RU2016129044A (ru) 2018-01-23
DK3082850T3 (da) 2019-10-07
IL246170B (en) 2019-06-30
CA2932388A1 (en) 2015-06-25
KR20160130979A (ko) 2016-11-15
US20160317634A1 (en) 2016-11-03
LT3082850T (lt) 2019-11-11
MX2016007939A (es) 2016-10-28
US20180064794A1 (en) 2018-03-08
JP6662787B2 (ja) 2020-03-11
WO2015090584A1 (en) 2015-06-25
EP3082850A1 (en) 2016-10-26
IL246170A0 (en) 2016-07-31
US10441645B2 (en) 2019-10-15
BR112016014405A2 (pt) 2018-02-20
AU2014365900A1 (en) 2016-07-14
JP2017502692A (ja) 2017-01-26
ES2747772T3 (es) 2020-03-11
HUE045567T2 (hu) 2020-01-28
EP3082850B1 (en) 2019-08-28
CN106061500A (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
IL246170A0 (en) A new msln-targeted DNA vaccine for cancer immunotherapy
IL235890A0 (en) vaccine
SG10201911616QA (en) Individualized vaccines for cancer
GB201315946D0 (en) Oncology vaccine
GB201223386D0 (en) Vaccine
SG11201500396TA (en) Tumor vaccination
ZA201500656B (en) Marker vaccine
ZA201408335B (en) Multivalent breast cancer vaccine
IL241109A0 (en) Targeted vaccines for veterinary use
SG11201401632WA (en) Antigen presenting cancer vaccine
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
SMT202100545T1 (it) Vaccini contro il cancro mirati alle cellule staminali cancerose
PL3473267T3 (pl) Zindywidualizowane szczepionki przeciwnowotworowe
GB201301125D0 (en) Methods for improving the efficency of gene targeting
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine